| Qualification Type: | PhD |
|---|---|
| Location: | Exeter |
| Funding for: | UK Students, International Students |
| Funding amount: | £21,805 The studentship will provide funding of fees and a stipend of £21,805 per annum for 2026/7. |
| Hours: | Full Time |
| Placed On: | 28th October 2026 |
|---|---|
| Closes: | 8th December 2026 |
| Reference: | 6025 |
Background
Cancer cells often depend on specific genes to survive, making those genes attractive drug targets. CRISPR screens knock out genes to measure their importance for cancer cell survival, and large efforts such as DepMap and Project Score have mapped individual single‑gene dependencies across many cancer models. However, single‑gene studies miss vulnerabilities that only appear when two genes are disrupted together. These genetic interactions (GIs), including synthetic lethality, are a rich but under‑explored source of oncology targets.
As testing ~400 million gene pairs is infeasible, computational prediction is essential. Current GI prediction methods combine limited pairwise screens with larger single‑gene screens but rely on low‑dimensional readouts and generalise poorly across disease contexts(1).
By contrast, a proof‑of‑concept study showed that perturb‑seq, which couples CRISPR editing with single‑cell transcriptomics, can support GI prediction using recommender‑system approaches(2). Near genome‑wide perturb‑seq datasets are now available(3, 4), providing transcriptome‑wide readouts that could enable scalable, accurate prediction models.
Objectives
Expected outcomes
You will gain
An interdisciplinary project
The main supervisor is an expert in statistical and machine‑learning methods for genome editing; the co‑supervisor specialises in statistics, reproducible coding and model evaluation. FGC supervisors (Dr Kalinka, Dr Ross‑Thriepland, Dr Walter) will provide additional expertise in genome editing, genomics, cancer biology and bioinformatics.
Facilities and Resources
The University of Exeter will provide high performance computing for model development and training. The FGC will provide world-leading CRISPR and single cell screening facilities and technical expertise.
Funded by: MRC Medical Research Council
Type / Role:
Subject Area(s):
Location(s):